Skip to content
← Holders

Patient Square Capital LP

What Patient Square Capital LP reported holding on Form 13F for the quarter ended Sep 30, 2026.

CIK 1819257 · Filed Nov 10, 2026

Positions
23
Reported value
$626.7M
Opened
6
Closed
6
Other managers included
0

Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR

Quarters on file

  1. Sep 30, 2025$373.9M
    24 positions
  2. Dec 31, 2025$467.1M
    28 positions
  3. Mar 31, 2026$563.6M
    29 positions
  4. Jun 30, 2026$645.5M
    23 positions
  5. Sep 30, 2026$626.7M
    23 positions
SecuritySharesChangeValueOf portfolio
ROIVRoivant Sciences Ltd.
7.7M−3.9%$282M45%
RVMDRevolution Medicines, Inc.
196K−29.0%$40.2M6.4%
UTHRUnited Therapeutics Corp
62.7K+68.8%$34M5.4%
ARGXArgenx SE
28K+21.7%$26.8M4.3%
PHVSPharvaris N.V.
808.6K+20.5%$25.7M4.1%
ABVXAbivax S.A.
243K+17.7%$24.1M3.8%
BLTEBelite Bio, Inc
131.7K+19.7%$22.4M3.6%
MIRMMirum Pharmaceuticals, Inc.
234K−10.2%$20M3.2%
ZLABZai Lab Ltd
591.5KNew$15.6M2.5%
DFTXDefinium Therapeutics, Inc.
385KNew$14.7M2.3%
CMPSCOMPASS Pathways plc
1.1MNew$13.1M2.1%
DBVTDBV Technologies S.A.
1.1M+21.6%$13M2.1%
ONCBeOne Medicines Ltd.
33.5K−62.8%$12.3M2%
COGTCogent Biosciences, Inc.
361.9K−14.8%$11.6M1.8%
RCUSArcus Biosciences, Inc.
410K+15.2%$10.6M1.7%
BNTXBioNTech SE
105.4K−21.6%$10.4M1.7%
ELVNEnliven Therapeutics, Inc.
212.5K±0%$9.7M1.6%
PCVXVaxcyte, Inc.
166KNew$9.4M1.5%
KYMRKymera Therapeutics, Inc.
84K+76.8%$9.4M1.5%
ALLOAllogene Therapeutics, Inc.
4.6M−9.9%$7.3M1.2%
ZNTLZentalis Pharmaceuticals, Inc.
2MNew$5.6M0.9%
IVAInventiva S.A.
1.2M−37.9%$4.5M0.7%
HROWHarrow, Inc.
145KNew$4.5M0.7%